We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Predicts Response to Immunotherapy in Patients with Non-Small Cell Lung Cancer

By LabMedica International staff writers
Posted on 24 May 2022
Print article
Image: Blood-based tumor biomarker can predict immunotherapy benefit for NSCL Cancer (Photo courtesy of Northwestern University)
Image: Blood-based tumor biomarker can predict immunotherapy benefit for NSCL Cancer (Photo courtesy of Northwestern University)

Atezolizumab monotherapy, an immune checkpoint therapy, is an effective treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have high programmed death ligand 1 (PD-L1) expression. When PD-L1 is bound to the exterior of a cell, it tells roaming T-cells to leave the cell alone. Many cancers have upregulated PD-L1 to help hide cancer cells from the immune system. However, a biopsy is required to determine PD-L1 levels and as many as 30% of patients with NSCLC may not have enough high-quality tissue biopsied at diagnosis for accurate biomarker analyses. Now, a blood-based tumor biomarker can predict the benefits of immunotherapy to patients with NSCLC, according to a study.

In the trial, clinical scientists at the Northwestern University Feinberg School of Medicine (Chicago, IL, USA) enrolled 153 patients with NSCLC to analyze circulating tumor DNA (ctDNA) for tumor mutational burden (TMB), a measure of total mutations found in the DNA of cancer cells. Cancers with high TMB have been associated with a positive response to immune checkpoint inhibitor therapies. Of the patients, 28 had high TMB values - making them suitable for atezolizumab monotherapy - while 91 patients had low TMB values. Notably, the high TMB group was slightly younger and had more smokers. All patients received atezolizumab monotherapy, and response rates to the therapy were much higher in the high TMB group - 35.7% compared to just 5.5% in the low TMB group. Patients in the high TMB group also experienced longer survival than those in the low TMB group.

The findings demonstrate that measuring TMB in ctDNA is a viable option for stratifying patients for immune checkpoint inhibitor therapy, according to the investigators. While more work is required to understand the relationship between TMB and immune checkpoint inhibitor therapy - hopefully revealing a sub-population of patients who would benefit most from the therapy - the foundations for therapy selection using a simple blood test are strong,

“The findings from this study will help us identify and design better blood-based biomarkers in immuno-oncology,” said Young Kwang Chae, MD, MPH, MBA, associate professor of Medicine in the Division of Hematology and Oncology and a co-author of the study. “It will allow the right therapy to be delivered to the right group of patients.”

Related Links:
Northwestern University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.